FDA Warns Of Increased Risk Of Thigh Bone Fracture After Surgery With Use Of Zimmer Biomet CPT Hip System Femoral Stem 12/14 Ne
Portfolio Pulse from Benzinga Newsdesk
The FDA has issued a warning about an increased risk of thigh bone fractures associated with the use of Zimmer Biomet's CPT Hip System Femoral Stem 12/14 Ne after surgery. This could impact Zimmer Biomet's reputation and sales.
September 17, 2024 | 6:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA has warned about an increased risk of thigh bone fractures with Zimmer Biomet's CPT Hip System Femoral Stem 12/14 Ne. This could negatively impact Zimmer Biomet's reputation and sales.
The FDA warning directly affects Zimmer Biomet's product, potentially leading to decreased sales and damage to the company's reputation. This could result in a short-term negative impact on ZBH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90